These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 12657113)
1. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. Elkas JC; Holschneider CH; Katz B; Li AJ; Louie R; McGonigle KF; Berek JS Int J Gynecol Cancer; 2003; 13(2):138-41. PubMed ID: 12657113 [TBL] [Abstract][Full Text] [Related]
2. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients. Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658 [TBL] [Abstract][Full Text] [Related]
3. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982 [TBL] [Abstract][Full Text] [Related]
12. The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence Guidance 2001: the Nottingham experience. Anand A; Chan SY Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):543-8. PubMed ID: 15630848 [TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766 [TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699 [TBL] [Abstract][Full Text] [Related]
15. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Rodriguez M; Rose PG Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080 [TBL] [Abstract][Full Text] [Related]
16. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience. Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918 [TBL] [Abstract][Full Text] [Related]
17. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Gronlund B; Hansen HH; Høgdall C; Engelholm SA Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013 [TBL] [Abstract][Full Text] [Related]
19. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Brown JV; Peters WA; Rettenmaier MA; Graham CL; Smith MR; Drescher CW; Micha JP Gynecol Oncol; 2003 Feb; 88(2):136-40. PubMed ID: 12586592 [TBL] [Abstract][Full Text] [Related]